This site is intended only for healthcare professionals resident in the United Kingdom

Information relating to specific disease areas aligned to Pfizer’s portfolio and other resources designed for Pfizer medicines.

See all Therapy areas

Learn about ATTR-CM and uncover the differences between hereditary and Wild-type ATTR-CM

Learn about the red flags that may raise suspicion of and techniques used to diagnose ATTR-CM

Explore a range of educational resources to support the diagnosis of ATTR-CM

Click here for Vyndaqel®▼ (tafamidis) Prescribing Information. Adverse event reporting information can be found at the bottom of the page.

Expert videos

Dr Robert Cooper (Liverpool Heart and Chest Hospital, Liverpool)

Imaging techniques for diagnosis of cardiac amyloidosis

'Ask the expert' video from the 2020 BSH Congress Symposium with Rob Cooper. Rob highlights the symptoms of cardiac amyloidosis and provides an in-depth explanation of the imaging techniques used in combination to diagnose cardiac amyloidosis accurately.

Dr Lisa Anderson (St George's Hospital, London) ​​​​​​​

Tips for Detecting Transthyretin Amyloid Cardiomyopathy (ATTR-CM)

Summary video from the 2020 BSH Congress Symposium with Lisa Anderson, who shares some important tips for helping you to detect TTR cardiac amyloidosis, including example criteria of a patients history.

Building the knowledge: Biological foundations of ATTR amyloidosis

This module reviews the biological foundation and disease mechanism of ATTR amyloidosis.

Building the knowledge: Navigating the ATTR amyloidosis landscape

This video reviews the disease landscape, and highlights differences between wtATTR amyloidosis and hATTR amyloidosis.

Building the knowledge: One disease with many faces

​​​​​​​This video breaks down the various types of ATTR amyloidosis and the clinical clues that can raise suspicion of ATTR-CM.

Building the knowledge: ​​​​​​​The patient journey to diagnosis of ATTR-CM, a race against time

This module reviews the importance of an early diagnosis of ATTR-CM.

Building the knowledge: Appropriately diagnosing ATTR-CM

The last in the series video reviews non-invasive and invasive approaches for the diagnosis of ATTR-CM.

Dr Pablo Garcia-Pavia (Hospital Puerta de Hierro, Madrid)

Revealing ATTR-CM in Clinical Practice: Seeing the Signs
​​​​​​​

Dr Pablo Garcia-Pavia presents an overview of amyloidosis and highlights the clinical clues that raise suspicion of transthyretin amyloid cardiomyopathy (ATTR-CM). He also introduces the case of a patient with suspected ATTR-CM.

Dr Pablo Garcia-Pavia (Hospital Puerta de Hierro, Madrid)

Revealing ATTR-CM in Clinical Practice: Confirming the Diagnosis
​​​​​​​

Dr Pablo Garcia-Pavia reviews selected non-invasive and invasive approaches to diagnosing transthyretin amyloid cardiomyopathy (ATTR-CM), to help clinicians put the clues together and unmask ATTR-CM in practice.  He also introduces the case of a patient with suspected ATTR-CM.

Explore more

See other educational resources available

Explore more

PP-VYN-GBR-0892. October 2021

Quick Links

Register to receive tailored marketing information from Pfizer by email

Stay up to date with the latest relevant healthcare, medical and promotional information about medicines and vaccines promoted by Pfizer.

PP-PFE-GBR-2809. October 2020

Sign up now

For UK Healthcare Professionals*

These pages are not intended for patients or for members of the general public. The healthcare professional web pages contain promotional content.

I confirm that I am a healthcare professional* resident in the United Kingdom.

If you select 'No', you will be redirected to Pfizer.co.uk where you will be able to access reference information on Pfizer's prescription medicines.

*The ABPI Code definition for healthcare professional is members of the medical, dental, pharmacy and nursing professionals and any other persons who in the course of their professional activities may administer, prescribe, purchase, recommend or supply a medicine.

PP-PFE-GBR-2688. December 2020

Yes

No